ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer

20260 citationsJournal Articlegold Open Access

Authors

Takahiro Ohashi · Zenyaku Kogyo (Japan)

T. Nagasaki · Zenyaku Kogyo (Japan)

Kayoko Kawai-Asami · Zenyaku Kogyo (Japan)

Kotomi Akatsuka · Zenyaku Kogyo (Japan)

Yuko Nagata · Zenyaku Kogyo (Japan)

Sayuri Terada · Zenyaku Kogyo (Japan)

Shinsuke Hiramoto ·

Abstract

ZSTK3744 was identified through screening for its cell growth-inhibitory activity on chemotherapy-resistant TNBC cells. ZSTK3744 exerts its activity through AhR. ZSTK3744 exhibits superior cell growth-inhibitory activity compared with other AhR agonists and demonstrates a favorable safety profile. Therefore, ZSTK3744 is a promising therapeutic agent for overcoming chemotherapy resistance in TNBC.

Topics & Keywords

Toxic Organic Pollutants Impact Eicosanoids and Hypertension Pharmacology Glutathione Transferases and Polymorphisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer Research Communications

Volume 6, Issue 2, pp. 421-436

DOI: 10.1158/2767-9764.crc-25-0119

Field-Weighted Citation Impact: 0.00